Literature DB >> 10816430

Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides.

T Tokuda1, M Calero, E Matsubara, R Vidal, A Kumar, B Permanne, B Zlokovic, J D Smith, M J Ladu, A Rostagno, B Frangione, J Ghiso.   

Abstract

The inheritance of the apolipoprotein E (apoE) epsilon4 allele is a prevailing risk factor for sporadic and familial Alzheimer's disease (AD). ApoE isoforms bind directly to Alzheimer's amyloid beta (Abeta) peptides both in vitro and in vivo. Recent studies suggest that association of apoE with lipids may modulate its interaction with Abeta. We examined the binding of lipid-associated and delipidated apoE3 and apoE4 isoforms to Abeta utilizing a solid-phase binding assay and estimated the dissociation constants for the interaction of various apoE and Abeta species. Using native apoE isoforms from stably transfected RAW 264 and human embryonic kidney 293 cells, apoE3 had greater affinity than apoE4 for both Abeta1-40 and Abeta1-42. Delipidation of apoE decreased its affinity for Abeta peptides by 5-10-fold and abolished the isoform-specificity. Conversely, incorporation of apoE isoforms produced by baculovirus-infected Sf9 cells into reconstituted human high-density-lipoprotein lipoparticles restored the affinity values for Abeta peptides and resulted in preferential binding of apoE3. The data demonstrate that native lipid-associated apoE3 binds to Abeta peptides with 2-3-fold higher affinity than lipid-associated apoE4. Since the isoforms' binding efficiency correlate inversely with the risk of developing late-onset AD, the results suggest a possible involvement of apoE3 in the clearance or routing out of Abeta from the central nervous system as one of the mechanisms underlying the pathology of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10816430      PMCID: PMC1221074     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  47 in total

1.  Self-associated tetramer of human apolipoprotein E does not lead to its accumulation on a lipid particle.

Authors:  S Yokoyama
Journal:  Biochim Biophys Acta       Date:  1990-10-22

2.  Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning.

Authors:  J Poirier; M Hess; P C May; C E Finch
Journal:  Brain Res Mol Brain Res       Date:  1991-09

3.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

Authors:  E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Science       Date:  1993-08-13       Impact factor: 47.728

4.  Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid.

Authors:  T Wisniewski; B Frangione
Journal:  Neurosci Lett       Date:  1992-02-03       Impact factor: 3.046

5.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease.

Authors:  Y Namba; M Tomonaga; H Kawasaki; E Otomo; K Ikeda
Journal:  Brain Res       Date:  1991-02-08       Impact factor: 3.252

6.  Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid.

Authors:  T Wisniewski; A Golabek; E Matsubara; J Ghiso; B Frangione
Journal:  Biochem Biophys Res Commun       Date:  1993-04-30       Impact factor: 3.575

7.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.

Authors:  A M Saunders; W J Strittmatter; D Schmechel; P H George-Hyslop; M A Pericak-Vance; S H Joo; B L Rosi; J F Gusella; D R Crapper-MacLachlan; M J Alberts
Journal:  Neurology       Date:  1993-08       Impact factor: 9.910

8.  Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids.

Authors:  P Seubert; C Vigo-Pelfrey; F Esch; M Lee; H Dovey; D Davis; S Sinha; M Schlossmacher; J Whaley; C Swindlehurst
Journal:  Nature       Date:  1992-09-24       Impact factor: 49.962

9.  Production of the Alzheimer amyloid beta protein by normal proteolytic processing.

Authors:  M Shoji; T E Golde; J Ghiso; T T Cheung; S Estus; L M Shaffer; X D Cai; D M McKay; R Tintner; B Frangione
Journal:  Science       Date:  1992-10-02       Impact factor: 47.728

10.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

View more
  101 in total

1.  Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift.

Authors:  Mary Jo LaDu; Gregory W Munson; Lisa Jungbauer; Godfrey S Getz; Catherine A Reardon; Leon M Tai; Chunjiang Yu
Journal:  Biochim Biophys Acta       Date:  2011-11-23

2.  Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba.

Authors:  K Hall; J Murrell; A Ogunniyi; M Deeg; O Baiyewu; S Gao; O Gureje; J Dickens; R Evans; V Smith-Gamble; F W Unverzagt; J Shen; H Hendrie
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

3.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

Authors:  R B DeMattos; K R Bales; D J Cummins; J C Dodart; S M Paul; D M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

Review 4.  Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease.

Authors:  Evan Dorey; Nina Chang; Qing Yan Liu; Ze Yang; Wandong Zhang
Journal:  Neurosci Bull       Date:  2014-03-20       Impact factor: 5.203

5.  A flow cytometry-based in vitro assay reveals that formation of apolipoprotein E (ApoE)-amyloid beta complexes depends on ApoE isoform and cell type.

Authors:  Eleanna Kara; Jordan D Marks; Allyson D Roe; Caitlin Commins; Zhanyun Fan; Maria Calvo-Rodriguez; Susanne Wegmann; Eloise Hudry; Bradley T Hyman
Journal:  J Biol Chem       Date:  2018-06-27       Impact factor: 5.157

6.  Association of ApoE and LRP mRNA levels with dementia and AD neuropathology.

Authors:  Afia Akram; James Schmeidler; Pavel Katsel; Patrick R Hof; Vahram Haroutunian
Journal:  Neurobiol Aging       Date:  2011-06-15       Impact factor: 4.673

7.  Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.

Authors:  Joseph M Castellano; Jungsu Kim; Floy R Stewart; Hong Jiang; Ronald B DeMattos; Bruce W Patterson; Anne M Fagan; John C Morris; Kwasi G Mawuenyega; Carlos Cruchaga; Alison M Goate; Kelly R Bales; Steven M Paul; Randall J Bateman; David M Holtzman
Journal:  Sci Transl Med       Date:  2011-06-29       Impact factor: 17.956

Review 8.  ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?

Authors:  Takahisa Kanekiyo; Huaxi Xu; Guojun Bu
Journal:  Neuron       Date:  2014-02-19       Impact factor: 17.173

9.  A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; James A Ripellino; Yongsheng Li; Stephen D Schmidt; Paul M Mathews; John D Fryer; David M Holtzman; Einar M Sigurdsson; Thomas Wisniewski
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

10.  Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease.

Authors:  Suzanne E Wahrle; Hong Jiang; Maia Parsadanian; Jungsu Kim; Aimin Li; Amanda Knoten; Sanjay Jain; Veronica Hirsch-Reinshagen; Cheryl L Wellington; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.